Navigation Links
PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments
Date:10/4/2007

PC-LDM ENSURES COMPLIANCE WITH THE SEND FORMAT FOR DATA EXCHANGE AND

ELECTRONIC SUBMISSIONS

FOSTER CITY, Calif., Oct. 4 /PRNewswire/ -- PointCross announced today the release of its PC-LDM(TM) Suite that allows Pharmaceutical and Biotechnology companies to instantly become compliant with SEND (Standard for Exchange of Non-Clinical Data), a CDISC (Clinical Data Interchange Standards Consortium) standard. FDA is anticipating that SEND will replace its current paper or PDF submission formats as indicated in the Federal Register Notice for a Regulatory SEND Pilot (http://www.fda.gov/OHRMS/DOCKETS/98fr/E7-19468.pdf).

Besides SEND compliance, PC-LDM enables global companies to plan the pipeline of studies, exercise control over the conduct of studies, improve study quality, and gain visibility into study progress internally or at a CRO in a highly secure manner. It provides a single, secure environment to orchestrate multi-party workflows, and stakeholder interactions within an individual company, or across the extended enterprise including CROs.

PC-LDM is available either as a SaaS (Software-as-a-Service) model, or deployed within the enterprise.

"The FDA yesterday announced a Regulatory pilot to test the SEND standard and tools for submission and review of nonclinical data including animal toxicology and carcinogenicity data," said Seema Handu, Ph.D., of PointCross. "As the FDA moves towards data-centric electronic submissions, it is essential for sponsor companies to manage their study data throughout the lifecycle of a drug in a standard consistent manner," Dr. Handu added. Dr. Handu has led the SEND Team, a CDISC Working Committee, since its inception in 2002.

"PC-LDM will enable sponsor companies to meet FDA's requirements around SEND as well as other formats that may be required by other agencies," said Shree Nath, Ph.D. "PC-LDM's Semantic Data Exchanger allows data from legacy and on-going studies to be readily available for analysis and data mining, study comparison across similar chemical structures, decision making, and knowledge re-use. This is invaluable considering the amount of information loss due to legacy applications being retired, data currently locked permanently in documents, and inconsistent use of scientific terms by different CROs and individual scientists," added Dr. Nath.

PointCross' PC-LDM offering is built on Orchestra(TM), a scalable, secure SOA platform that provides core capabilities for defining, executing, analyzing and interpreting pre-clinical studies. PC-LDM includes vendor neutral XML-based Operational Data Models (ODMs) for all pre-clinical study types. It allows data exchange across industry standard applications and formats.

About PointCross

PointCross (http://www.pointcross.com) provides advanced strategic business solutions implemented on its Orchestra(TM) platform to knowledge-intensive industries including Pharmaceutical R&D and Upstream Oil and Gas. Besides PC-LDM, PointCross' IDDS (Integrated Drug Development Suite) includes other solutions for specific business processes within the R&D chain such as Lead Optimization, CMC Workbench, and Portfolio/Resource Management. Our customers have realized excellent ROIs and IRRs by using our solutions.


'/>"/>
SOURCE PointCross
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sweet corn releases antioxidants on cooking
2. An International Growth Standard For Childs Releases By WHO
3. The National Governors Association Releases Guidelines For Outbreak Of Bird Flu
4. Eli Lilly Releases Digital Insulin Pen
5. CDC To Conduct Pre-clinical Trails Of BioDiems Intranasal Bird Flu Vaccine
6. Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress
7. Rural Canadians travel far for specialists: study
8. A new study surpasses Gene Therapy Hurdle
9. Tomato Sauce reduces Cancer Risk- Study
10. A question on study of Adult Stem Cell
11. Study on obesity and heart failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... Switzerland (PRWEB) , ... March 27, 2017 , ... ... food industry. Conventional sodium testing methods are complicated and require expert user knowledge. ... a new analytical method dedicated to the simplified, yet highly accurate, determination of ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/27/2017)... ... 2017 , ... Harris Communications, Inc., a leading provider of assistive technology ... the Deaf Seniors of America Conference, April 4-7 at the Hotel Westin Galleria in ... friendly staff from Harris Communications and to try out the newest assistive devices available ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce the ... subjects. The ELITE DXA has an active scan window, which is more than double ... fit in the scan area could not undergo an accurate total body bone density or ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Sophiris Bio Inc. (NASDAQ: ... clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for ... reported fourth quarter and full year 2016 financial ... Key Corporate Highlights: Advanced Topsalysin ... During 2016, the Company reported successful results with ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... , March 27, 2017 The staggering cost ... wealthiest countries have access to the latest treatment options ... the US, many patients have inadequate or no health ... skip therapy altogether. Access to modern cancer treatment is ... countries. The mission statements of pharmaceutical ...
Breaking Medicine Technology: